Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Immunology & Inflammation

Mescaline for Immunology & Inflammation

5 papers and 0 clinical trials exploring mescaline as a treatment for immunology & inflammation.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

5 papers
Paywallindividual

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

This case report (n=3) documents the first academic instances of olfactory improvement after psychedelic use. The study also discusses potential mechanisms, such as serotonergic effects, neuroplasticity, and anti-inflammatory effects, suggesting further research into psychedelics for olfactory dysfunction.

Published
August 31, 2023
Journal
Journal of Psychoactive Drugs
Authors
Kovacevich, A., Weleff, J., Claytor, B., Barnett, B. S.
Open Accessindividual

Classic psychedelics do not affect T cell and monocyte immune responses

In vitro exposure to LSD, psilocin, DMT and mescaline did not alter proliferation or stimulated cytokine release of primary human T lymphocytes nor induce NF-κB in monocytes. These results indicate classic psychedelics do not directly modulate key T‑cell or monocyte functions and support their safe use in assisted psychotherapy where immune suppression would be detrimental.

Published
January 20, 2023
Journal
Frontiers in Psychiatry
Authors
Rudin, D., Areesanan, A., Liechti, M. E., Gründemann, C.
Paywallindividual

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Using nationally representative US survey data (NSDUH 2005–2014), lifetime use of classic psychedelics was associated with lower odds of past‑year hypertension after adjustment (adjusted odds ratio 0.86, 95% CI 0.81–0.91), an effect driven specifically by lifetime tryptamine use (aOR 0.80, 95% CI 0.73–0.89). These cross‑sectional findings suggest a potential protective link but cannot establish causality; randomised controlled trials are needed to probe mechanisms and causal effects on blood pressure.

Published
May 1, 2021
Journal
Hypertension
Authors
Simonsson, O., Hendricks, P. S., Carhart-Harris, R., Kettner, H., Osika, W.
Open Accessindividual

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

In a double‑blind placebo‑controlled trial of treatment‑resistant depression patients and healthy controls, ayahuasca produced a significant 48‑hour reduction in C‑reactive protein (CRP) and, in patients, larger CRP decreases correlated with greater reductions in depressive symptoms. No significant effects were seen for interleukin‑6 or BDNF, and these biomarkers did not predict antidepressant response or remission.

Published
July 10, 2020
Journal
Journal of Psychopharmacology
Authors
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão-Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., de Araujo, D. B.
Open Accessmeta

Psychedelics

This paper is the most comprehensive review of psychedelics research up to 2016 by the eminent David E. Nichols.

Published
April 1, 2016
Journal
Pharmacological Reviews
Authors
Nichols, D. E.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Immunology & Inflammation yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Immunology & Inflammation trials Full Mescaline profile Full Immunology & Inflammation profile